Literature DB >> 31822581

Long-term prognosis of ulcerative colitis and its temporal changes between 1986 and 2015 in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea.

Jae Myung Cha1, Sang Hyoung Park2, Kyoung Hoon Rhee3, Sung Noh Hong4, Young-Ho Kim4, Seung In Seo5, Kyung Ho Kim5, Seung Kyu Jeong6, Ji Hyun Lee7, Sun Yong Park8, Hyunju Park9, Joo Sung Kim10, Jong Pil Im10, Hyuk Yoon11, Sung Hoon Kim12, Jisun Jang12, Jeong Hwan Kim13, Seong O Suh14, Young Kyun Kim15, Byong Duk Ye2, Suk-Kyun Yang16.   

Abstract

OBJECTIVE: No population-based study has evaluated the natural course of UC over three decades in non-Caucasians. We aimed to assess the long-term natural course of Korean patients with UC in a population-based cohort.
DESIGN: This Korean population-based, Songpa-Kangdong IBD cohort included all patients (n=1013) newly diagnosed with UC during 1986-2015. Disease outcomes and their predictors were evaluated.
RESULTS: During the median follow-up of 105 months, the overall use of systemic corticosteroids, thiopurines and antitumour necrosis factor (anti-TNF) agents was 40.8%, 13.9% and 6.5%, respectively. Over time, the cumulative risk of commencing corticosteroids decreased, whereas that of commencing thiopurines and anti-TNF agents increased. During follow-up, 28.7% of 778 patients with proctitis or left-sided colitis at diagnosis experienced proximal disease extension. A total of 28 patients (2.8%) underwent colectomy, demonstrating cumulative risks of colectomy at 1, 5, 10, 20 and 30 years after diagnosis of 1.0%, 1.9%, 2.2%, 5.1% and 6.4%, respectively. Multivariate Cox regression analysis revealed that extensive colitis at diagnosis (HR 8.249, 95% CI 2.394 to 28.430), ever use of corticosteroids (HR 6.437, 95% CI 1.440 to 28.773) and diagnosis in the anti-TNF era (HR 0.224, 95% CI 0.057 to 0.886) were independent predictors of colectomy. The standardised mortality ratio in patients with UC was 0.725 (95% CI 0.508 to 1.004).
CONCLUSION: Korean patients with UC may have a better clinical course than Western patients, as indicated by a lower colectomy rate. The overall colectomy rate has continued to decrease over the past three decades. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  IBD clinical; epidemiology; surgery for IBD; ulcerative colitis

Mesh:

Substances:

Year:  2019        PMID: 31822581     DOI: 10.1136/gutjnl-2019-319699

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  10 in total

1.  Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.

Authors:  Jung Woo Shin; Joonho Jeong; Seok Won Jung; Seung Bum Lee; Bo Ryung Park; Min-Ju Kim; Eun Ji Park; Neung Hwa Park
Journal:  Dig Dis Sci       Date:  2020-06-10       Impact factor: 3.199

2.  Bifidobacterium Lactis Probio-M8 regulates gut microbiota to alleviate Alzheimer's disease in the APP/PS1 mouse model.

Authors:  Jianing Cao; William Kwame Amakye; Chunli Qi; Xiaojun Liu; Jie Ma; Jiaoyan Ren
Journal:  Eur J Nutr       Date:  2021-04-01       Impact factor: 5.614

3.  Trends in Worldwide Research in Inflammatory Bowel Disease Over the Period 2012-2021: A Bibliometric Study.

Authors:  Kemin Li; Chenzhe Feng; Haolin Chen; Yeqian Feng; Jingnan Li
Journal:  Front Med (Lausanne)       Date:  2022-05-19

4.  Venous Thromboembolism Risk in Asian Patients with Inflammatory Bowel Disease: A Population-Based Nationwide Inception Cohort Study.

Authors:  Su Young Kim; Yeon Seo Cho; Hyun-Soo Kim; Jung Kuk Lee; Hee Man Kim; Hong Jun Park; Hyunil Kim; Jihoon Kim; Dae Ryong Kang
Journal:  Gut Liver       Date:  2021-11-18       Impact factor: 4.321

5.  Progress towards elimination goals for viral hepatitis.

Authors:  Andrea L Cox; Manal H El-Sayed; Jia-Horng Kao; Jeffrey V Lazarus; Maud Lemoine; Anna S Lok; Fabien Zoulim
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-07-23       Impact factor: 46.802

Review 6.  Use of granulocyte/monocytapheresis in ulcerative colitis: A practical review from a European perspective.

Authors:  Eugeni Domènech; Joan-Ramon Grífols; Ayesha Akbar; Axel U Dignass
Journal:  World J Gastroenterol       Date:  2021-03-14       Impact factor: 5.742

7.  Prevalence and risk factors of bowel symptoms in Korean patients with ulcerative colitis in endoscopic remission: a retrospective study.

Authors:  Kwangwoo Nam; Sang Hyoung Park; Jun Ho Oh; Ho-Su Lee; Soomin Noh; Jae Cheol Park; Jin Yong Kim; Eun Hye Oh; Jeongseok Kim; Nam Seok Ham; Sung Wook Hwang; Dong-Hoon Yang; Byong Duk Ye; Jeong-Sik Byeon; Seung-Jae Myung; Suk-Kyun Yang
Journal:  BMC Gastroenterol       Date:  2021-01-06       Impact factor: 3.067

Review 8.  Inflammatory bowel disease in Korea: epidemiology and pathophysiology.

Authors:  Jung Won Lee; Chang Soo Eun
Journal:  Korean J Intern Med       Date:  2022-07-29       Impact factor: 3.165

9.  Trends in medication use and treatment patterns in Chinese patients with inflammatory bowel disease.

Authors:  Ling-Ya Yao; Bu-Le Shao; Feng Tian; Mei Ye; Yu-Qin Li; Xiao-Lei Wang; Lin Wang; Shao-Qi Yang; Xiao-Ping Lv; Yan Jia; Xue-Hong Wang; Xiao-Qi Zhang; Yan-Ling Wei; Qian Cao
Journal:  World J Gastroenterol       Date:  2022-08-14       Impact factor: 5.374

10.  Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis?

Authors:  Sang Hyoung Park; Byong Duk Ye; Suk-Kyun Yang
Journal:  Gut Liver       Date:  2022-01-15       Impact factor: 4.519

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.